Key result
PD-1 or PD-L1 inhibitors carry a ~1% incidence of potentially fatal myocarditis.
Why the study?
Immune checkpoint inhibitor-associated myocarditis is a rare and potentially fatal immune-related adverse event, motivating observation of its occurrence.
What is the incidence and clinical course of immune checkpoint inhibitor-associated myocarditis in patients receiving PD-1 or PD-L1 therapy?
Population
283 patients treated with PD-1 or PD-L1 monoclonal antibodies alone or combination therapy
Design
Single-center retrospective study
Authors
Loading...
Observational data underscore vigilance for fatal myocarditis with PD-1/PD-L1 inhibitors; leaves open optimal surveillance strategies in broader cohorts.
Cohort (n=283)
No
What is the incidence and clinical course of immune checkpoint inhibitor-associated myocarditis in patients receiving PD-1 or PD-L1 therapy?
ICI-associated myocarditis is a rare (1.06% incidence) but potentially fatal adverse event requiring early diagnosis and prompt glucocorticoid therapy.
Wang et al. (2020) conducted a cohort in Malignant tumors treated with PD-1 or PD-L1 inhibitors (n=283). PD-1 or PD-L1 monoclonal antibodies was evaluated on Incidence of ICI-associated myocarditis. Among 283 patients treated with PD-1 or PD-L1 inhibitors, the incidence of immune checkpoint inhibitor-associated myocarditis was 1.06% (3 cases), with two cases resulting in death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: